check_circleStudy Completed

Hyperphosphatemia

Bayer Identifier:

13287

ClinicalTrials.gov Identifier:

NCT01053676

EudraCT Number:

Not Available

EU CT Number:

Not Available
Bioequivalence study of BAY77-1931 granule

Trial purpose

The study is conducted as a randomized, non-blinded, 2-way crossover study. Target population is 60 Japanese healthy male adult subjects selected by screening examination which will be conducted within 4 weeks before the first drug administration of period 1 (before the hospitalization of period 1). Subjects will admit in the clinical institute on Day -3 and be discharged on Day 6 in each period. During hospitalization, standardized phosphate diet from Day -2 to Day 4 will start approximately 20 minutes before dosing. Subject will take about 1300 mg of phosphate evenly at breakfast lunch and dinner for each day. Subject should consume at least 95% of a meal. Distilled water not to include phosphate will be used for drinking water and meal. Subjects are to drink at least 1 L of distilled water every day in clinic to make sure enough urine volume. The 24 hours urine collection will be conducted between Day -2 and Day 4 to investigate the urinary phosphate excretion.BAY77-1931 granule 500 mg or Fosrenol chewable tablet 500 mg will be administered three times daily after each meal from Day 1 to Day 4. On day 4 single dose after breakfast will be administered. Study drugs will be administered immediately after each meal, that is within 20 minutes after start of each meal with 240 mL of distilled water. A Fosrenol chewable tablet 500 mg will be taken after chewing completely.

Key Participants Requirements

Sex

Male

Age

20 - 45 Years
  • - Japanese male volunteers who must have given their written informed consent to participate in the study
    - Age is between 20 and 45 years
    - Body Mass Index (BMI) is between 17.6 and 26.4 kg/m2.
    - Volunteers who are judged by the investigators to be suitable for enrollment in this clinical trial based upon the data from a screening test.
  • - A history of relevant diseases of internal organs (diseases that may significantly jeopardize body systems, such as severe liver or renal dysfunction, active peptic ulcer, ulcerative colitis, Crohn's disease, narrowing of colon lumen) or, of the central nervous system (e.g., epilepsy), or other organs which are likely to show inappropriateness for participation in this study
    - Conditions of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator (mental diseases that are thought to be ineligible for the communal life in the study participation, unable to consent to the participation, disables)
    - Known drug hypersensitivity or idiosyncrasy

Trial summary

Enrollment Goal
59
Trial Dates
January 2010 - April 2010
Phase
Phase 1
Could I Receive a placebo
No
Products
Fosrenol (Lanthanum Carbonate, BAY77-1931)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Osaka Pharmacology Clinical Research HospitalOsaka, 532-0003, Japan

Primary Outcome

  • Bioequivalence based on daily urinary phosphate excretion
    date_rangeTime Frame:
    Follow up examination cunducted on 7 to 10 days after the last drug administration
    enhanced_encryption
    Safety Issue:
    no

Secondary Outcome

  • Adverse event collection
    date_rangeTime Frame:
    Follow up examination cunducted on 7 to 10 days after the last drug administration
    enhanced_encryption
    Safety Issue:
    yes

Trial design

Bioequivalence study of BAY77-1931 granule - Randomized, non-blind, two-way, crossover study to establish the bioequivalence between BAY77-1931 granule 500 mg and Fosrenol chewable tablet 500 mg in Japanese healthy male adult subjects
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Open Label
Assignment
Crossover Assignment
Trial Arms
2

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer Healthcare products.